A global mechanism designed to make mpox vaccines available faster during outbreaks is due to begin operating in September 2026. The new stockpile is intended to replace an emergency-era workaround with a standing system that any country can ask to use, according to a joint announcement from the World Health Organization and its partners.
The initiative was launched on August 27 and announced publicly on September 2. It is funded by Gavi, the Vaccine Alliance, and coordinated through the International Coordinating Group on Vaccine Provision, or ICG. The group brings together WHO, UNICEF, the International Federation of Red Cross and Red Crescent Societies and Médecins Sans Frontières.
What the new mpox vaccine stockpile changes
A vaccine stockpile is more than a warehouse. Its practical value comes from having supply, financing and a decision process ready before the next urgent request arrives. When an outbreak occurs, a country can seek doses through an established allocation mechanism instead of negotiating from scratch while cases are rising.
WHO says the system is meant to provide timely, equitable and targeted access for outbreak response. Its partners will work with manufacturers and donors to decide the size and mix of the reserve, then assess requests so limited doses can be directed where they can have the greatest public-health effect. The mechanism may eventually help countries obtain diagnostics and related supplies as well.
The standing stockpile also gives vaccine makers and health agencies a clearer framework for future demand. That does not remove supply constraints, shipping delays or the operational work of vaccination campaigns. It does, however, reduce the number of arrangements that must be improvised during an emergency.
Why the partners created a long-term system
The ICG has coordinated emergency reserves for meningitis, cholera, yellow fever and Ebola. It was established in 1997 after major meningitis outbreaks showed the need for a shared process to manage scarce vaccines and antibiotics. Mpox is now being added to that model.
During the 2024 mpox public-health emergency, WHO and partners created a temporary Access and Allocation Mechanism. The new stockpile carries that work into a permanent structure. Gavi’s board approved financing in 2025, and the participating organizations later agreed to place the reserve under ICG governance.
The need remains substantial. WHO’s September 2 update says 145 countries and territories reported 190,683 confirmed cases and 529 deaths between January 1, 2022 and July 31, 2026. About two-thirds of reported cases were in the African Region. Those figures describe confirmed reports, not every infection, and reporting quality differs between countries.
How access decisions are expected to work
The ICG’s role is to weigh demand and outbreak impact while maintaining independence from any single buyer. WHO lists equity, speed, human rights, community leadership and context-specific collaboration among the principles guiding the mpox reserve.
That means a country’s ability to pay should not be the deciding factor. Gavi is financing the stockpile, while the operational partners bring experience in procurement, delivery, emergency medicine and vaccination programs. The coalition says all countries will be eligible to request support.
Approval of a request will not automatically put doses into arms. National authorities and their partners must still identify priority groups, maintain cold-chain conditions, train teams, communicate clearly with communities and monitor safety and coverage. Vaccination also works alongside surveillance, diagnosis, contact tracing, clinical care and risk communication; it is not a substitute for those measures.
What readers should understand about mpox
Mpox is caused by the monkeypox virus. It spreads mainly through close physical contact, including skin-to-skin and sexual contact, and can also spread through contaminated materials. Animal-to-human transmission continues in parts of Africa. Common symptoms can include a painful rash, fever, headache, muscle aches, low energy and swollen lymph nodes.
Many people recover, but severe disease can occur. Children, pregnant people and people with weakened immune systems can face higher risks. WHO recommends vaccination for people at high risk in an outbreak and, in some circumstances, after exposure. Exact eligibility and timing depend on national guidance and individual circumstances, so readers should use local health-authority advice rather than a news report for medical decisions.
The new reserve is therefore best understood as preparedness infrastructure: a way to shorten the distance between an outbreak request and a coordinated vaccine response. Its success will be measured not simply by how many doses are stored, but by whether countries receive suitable supplies quickly enough to interrupt transmission and protect those most likely to become seriously ill.
What remains unknown
The joint announcement does not yet specify the opening inventory, manufacturers, dose numbers or a standard delivery timeline. Those details will matter when the first requests are assessed. The partners also have to show that the permanent system can act faster and more equitably than the temporary arrangements used during earlier emergencies.
For now, the verifiable development is narrower but important: financing and governance are in place, the mechanism has been launched, and operations are scheduled to start later this month. It is not evidence that mpox has been eliminated or that vaccine access problems are solved.
Sources: WHO and partners’ September 2 joint release; WHO’s ICG mpox stockpile overview; Gavi’s announcement; WHO mpox fact sheet.
For more source-led public-health reporting, see our report on WHO’s child-friendly sickle cell treatment initiative.
Edin Pula
Edin Pula is the editor responsible for reviewing and publishing content at Smashology Media. He oversees sourcing, fact-checking, corrections, and editorial standards across coverage of internet culture, technology, entertainment, news, and crime.
